Drug Development

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by synaptic dysfunction and amyloid-beta (Aβ) plaque deposition.
• Current immunotherapies for AD have limitations, including amyloid-related imaging abnormalities.
• Small-molecule drugs offer a potentially safer and more cost-effective alternative for treating AD by disaggregating Aβ.

Purpose of the Study:

• To identify and evaluate novel small-molecule compounds for their efficacy in treating Alzheimer's disease.
• To assess the potential of the compound IK-5f as a therapeutic agent for reducing Aβ pathology and neuroinflammation.

Main Methods:

• Six novel compounds were synthesized and screened for anti-Aβ activity using Thioflavin T assays.
• The most effective compound, IK-5f, was administered to 5XFAD mice over four weeks.
• Cognitive function, Aβ plaque burden, and neuroinflammation were assessed using behavioral tests and biochemical analyses.

Main Results:

• IK-5f demonstrated significant inhibition of Aβ aggregation and promoted fibril dissociation in vitro.
• In vivo studies showed IK-5f improved cognitive performance in the Y-maze test in 5XFAD mice.
• IK-5f treatment reduced hippocampal Aβ plaque load and decreased markers of neuroinflammation.

Conclusions:

• IK-5f shows significant potential as a small-molecule therapeutic candidate for Alzheimer's disease.
• The compound effectively targets Aβ pathology and neuroinflammation.
• IK-5f demonstrates the ability to enhance cognitive function in AD models.